Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kyle Robles

Physician Assistant, Medical Spokane, WA Physician Assistant

NPI 1821645979 CMS profile 10844753

820 S McClellan St, Ste 200, Spokane, WA 99204

Open in the dashboard

General payments

$8,306

442 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Robles of Spokane, WA is reported in the CMS Open Payments database as having received $8,306 across 442 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $266 10
2024 General $1,106 49
2023 General $2,229 99
2022 General $2,663 148
2021 General $2,042 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Robles
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kyle Robles were reported at $266. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kyle Robles Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,042 $156 $41–$563 $132
2022 $2,663 $185 $55–$649 $149
2023 $2,229 $199 $58–$717 $160
2024 $1,106 $206 $62–$740 $164
2025 $266 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,135 57 payments
  2. AstraZeneca Pharmaceuticals LP $805 43 payments
  3. Novo Nordisk Inc $708 50 payments
  4. Janssen Pharmaceuticals, Inc $607 25 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $594 18 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $466 28 payments
  7. Novartis Pharmaceuticals Corporation $407 20 payments
  8. GlaxoSmithKline, LLC. $401 41 payments
  9. Amgen Inc. $353 19 payments
  10. Lilly USA, LLC $307 19 payments
  11. Other $2,523 122 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,292 441 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $552 47 payments
  2. UBRELVY $537 25 payments
  3. Ozempic $443 47 payments
  4. JARDIANCE $401 11 payments
  5. TRELEGY ELLIPTA $385 39 payments
  6. XIFAXAN $357 21 payments
  7. TRULANCE $357 21 payments
  8. QULIPTA $328 17 payments
  9. BREZTRI $316 14 payments
  10. LEQVIO $315 15 payments
  11. Other $6,810 346 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

4,512

Median for Physician Assistant: 241

Drug cost

$392,906

Median for Physician Assistant: $4,110

Branded share of claims

30.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 32 $53,345
Rybelsus Semaglutide Brand 17 $36,488
Eliquis Apixaban Brand 28 $31,323
Synjardy Empagliflozin/Metformin Hcl Brand 16 $26,709
Jardiance Empagliflozin Brand 16 $25,611
Relistor Methylnaltrexone Bromide Brand 11 $21,136
Synjardy Xr Empagliflozin/Metformin Hcl Brand 11 $19,487
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 25 $18,176
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 24 $15,139
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 17 $14,610

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$19,317

Medicare's payments for the services billed

Medicare patients

100

Average age 75

Services billed

327

53 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 24%
Depression 21%
Atrial fibrillation 20%
Diabetes 19%
Cancer 19%
Ischemic heart disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $143
$143 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $88
$88 16 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $82
$82 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $54
$54 — —
QULIPTA
  • AbbVie, Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

442 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record